Resuscitation outcomes consortium-amiodarone, lidocaine or placebo study (ROC-ALPS)

Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial

Peter J. Kudenchuk, Siobhan P. Brown, Mohamud Ramzan Daya, Laurie J. Morrison, Brian E. Grunau, Tom Rea, Tom Aufderheide, Judy Powell, Brian Leroux, Christian Vaillancourt, Jonathan Larsen, Lynn Wittwer, M. Riccardo Colella, Shannon W. Stephens, Mark Gamber, Debra Egan, Paul Dorian

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT). Methods ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ≥1 shock, and established vascular access to receive up to 450 mg amiodarone, 180 mg lidocaine, or placebo in the field using a double-blind protocol, along with standard resuscitation measures. The designated target population is all eligible randomized recipients of any dose of ALPS drug whose initial OHCA rhythm was VF/VT. A safety analysis includes all randomized patients regardless of their eligibility, initial arrhythmia, or actual receipt of ALPS drug. The primary outcome of ALPS is survival to hospital discharge; a secondary outcome is functional survival at discharge assessed as a modified Rankin Scale score ≤3. Results The principal aim of ALPS is to determine if survival is improved by amiodarone compared with placebo; secondary aim is to determine if survival is improved by lidocaine vs placebo and/or by amiodarone vs lidocaine. Prioritizing comparisons in this manner acknowledges where differences in outcome are most expected based on existing knowledge. Each aim also represents a clinically relevant comparison between treatments that is worth investigating. Conclusions Results from ALPS will provide important information about the choice and value of antiarrhythmic therapies for VF/VT arrest with direct implications for resuscitation guidelines and clinical practice.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume167
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Out-of-Hospital Cardiac Arrest
Amiodarone
Anti-Arrhythmia Agents
Lidocaine
Resuscitation
Ventricular Fibrillation
Ventricular Tachycardia
Placebos
Survival
Shock
Pharmaceutical Preparations
Health Services Needs and Demand
North America
Practice Guidelines
Blood Vessels
Cardiac Arrhythmias
Safety
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Resuscitation outcomes consortium-amiodarone, lidocaine or placebo study (ROC-ALPS) : Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial. / Kudenchuk, Peter J.; Brown, Siobhan P.; Daya, Mohamud Ramzan; Morrison, Laurie J.; Grunau, Brian E.; Rea, Tom; Aufderheide, Tom; Powell, Judy; Leroux, Brian; Vaillancourt, Christian; Larsen, Jonathan; Wittwer, Lynn; Colella, M. Riccardo; Stephens, Shannon W.; Gamber, Mark; Egan, Debra; Dorian, Paul.

In: American Heart Journal, Vol. 167, No. 5, 2014.

Research output: Contribution to journalArticle

Kudenchuk, PJ, Brown, SP, Daya, MR, Morrison, LJ, Grunau, BE, Rea, T, Aufderheide, T, Powell, J, Leroux, B, Vaillancourt, C, Larsen, J, Wittwer, L, Colella, MR, Stephens, SW, Gamber, M, Egan, D & Dorian, P 2014, 'Resuscitation outcomes consortium-amiodarone, lidocaine or placebo study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial', American Heart Journal, vol. 167, no. 5. https://doi.org/10.1016/j.ahj.2014.02.010
Kudenchuk, Peter J. ; Brown, Siobhan P. ; Daya, Mohamud Ramzan ; Morrison, Laurie J. ; Grunau, Brian E. ; Rea, Tom ; Aufderheide, Tom ; Powell, Judy ; Leroux, Brian ; Vaillancourt, Christian ; Larsen, Jonathan ; Wittwer, Lynn ; Colella, M. Riccardo ; Stephens, Shannon W. ; Gamber, Mark ; Egan, Debra ; Dorian, Paul. / Resuscitation outcomes consortium-amiodarone, lidocaine or placebo study (ROC-ALPS) : Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial. In: American Heart Journal. 2014 ; Vol. 167, No. 5.
@article{edcb2f4097c345328663a01daf71b840,
title = "Resuscitation outcomes consortium-amiodarone, lidocaine or placebo study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial",
abstract = "Background Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT). Methods ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ≥1 shock, and established vascular access to receive up to 450 mg amiodarone, 180 mg lidocaine, or placebo in the field using a double-blind protocol, along with standard resuscitation measures. The designated target population is all eligible randomized recipients of any dose of ALPS drug whose initial OHCA rhythm was VF/VT. A safety analysis includes all randomized patients regardless of their eligibility, initial arrhythmia, or actual receipt of ALPS drug. The primary outcome of ALPS is survival to hospital discharge; a secondary outcome is functional survival at discharge assessed as a modified Rankin Scale score ≤3. Results The principal aim of ALPS is to determine if survival is improved by amiodarone compared with placebo; secondary aim is to determine if survival is improved by lidocaine vs placebo and/or by amiodarone vs lidocaine. Prioritizing comparisons in this manner acknowledges where differences in outcome are most expected based on existing knowledge. Each aim also represents a clinically relevant comparison between treatments that is worth investigating. Conclusions Results from ALPS will provide important information about the choice and value of antiarrhythmic therapies for VF/VT arrest with direct implications for resuscitation guidelines and clinical practice.",
author = "Kudenchuk, {Peter J.} and Brown, {Siobhan P.} and Daya, {Mohamud Ramzan} and Morrison, {Laurie J.} and Grunau, {Brian E.} and Tom Rea and Tom Aufderheide and Judy Powell and Brian Leroux and Christian Vaillancourt and Jonathan Larsen and Lynn Wittwer and Colella, {M. Riccardo} and Stephens, {Shannon W.} and Mark Gamber and Debra Egan and Paul Dorian",
year = "2014",
doi = "10.1016/j.ahj.2014.02.010",
language = "English (US)",
volume = "167",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Resuscitation outcomes consortium-amiodarone, lidocaine or placebo study (ROC-ALPS)

T2 - Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial

AU - Kudenchuk, Peter J.

AU - Brown, Siobhan P.

AU - Daya, Mohamud Ramzan

AU - Morrison, Laurie J.

AU - Grunau, Brian E.

AU - Rea, Tom

AU - Aufderheide, Tom

AU - Powell, Judy

AU - Leroux, Brian

AU - Vaillancourt, Christian

AU - Larsen, Jonathan

AU - Wittwer, Lynn

AU - Colella, M. Riccardo

AU - Stephens, Shannon W.

AU - Gamber, Mark

AU - Egan, Debra

AU - Dorian, Paul

PY - 2014

Y1 - 2014

N2 - Background Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT). Methods ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ≥1 shock, and established vascular access to receive up to 450 mg amiodarone, 180 mg lidocaine, or placebo in the field using a double-blind protocol, along with standard resuscitation measures. The designated target population is all eligible randomized recipients of any dose of ALPS drug whose initial OHCA rhythm was VF/VT. A safety analysis includes all randomized patients regardless of their eligibility, initial arrhythmia, or actual receipt of ALPS drug. The primary outcome of ALPS is survival to hospital discharge; a secondary outcome is functional survival at discharge assessed as a modified Rankin Scale score ≤3. Results The principal aim of ALPS is to determine if survival is improved by amiodarone compared with placebo; secondary aim is to determine if survival is improved by lidocaine vs placebo and/or by amiodarone vs lidocaine. Prioritizing comparisons in this manner acknowledges where differences in outcome are most expected based on existing knowledge. Each aim also represents a clinically relevant comparison between treatments that is worth investigating. Conclusions Results from ALPS will provide important information about the choice and value of antiarrhythmic therapies for VF/VT arrest with direct implications for resuscitation guidelines and clinical practice.

AB - Background Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT). Methods ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ≥1 shock, and established vascular access to receive up to 450 mg amiodarone, 180 mg lidocaine, or placebo in the field using a double-blind protocol, along with standard resuscitation measures. The designated target population is all eligible randomized recipients of any dose of ALPS drug whose initial OHCA rhythm was VF/VT. A safety analysis includes all randomized patients regardless of their eligibility, initial arrhythmia, or actual receipt of ALPS drug. The primary outcome of ALPS is survival to hospital discharge; a secondary outcome is functional survival at discharge assessed as a modified Rankin Scale score ≤3. Results The principal aim of ALPS is to determine if survival is improved by amiodarone compared with placebo; secondary aim is to determine if survival is improved by lidocaine vs placebo and/or by amiodarone vs lidocaine. Prioritizing comparisons in this manner acknowledges where differences in outcome are most expected based on existing knowledge. Each aim also represents a clinically relevant comparison between treatments that is worth investigating. Conclusions Results from ALPS will provide important information about the choice and value of antiarrhythmic therapies for VF/VT arrest with direct implications for resuscitation guidelines and clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84899495190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899495190&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2014.02.010

DO - 10.1016/j.ahj.2014.02.010

M3 - Article

VL - 167

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -